Insilico Medicine, a pioneering clinical-stage biotechnology company specializing in generative artificial intelligence (AI) for drug discovery, has announced a significant expansion of its collaboration with Tenacia Biotechnology (Hong Kong) Co., Limited, a commercial-stage biopharmaceutical firm dedicated to creating therapeutics for complex and underserved neurological disorders. Building on a productive initial collaboration that began in March 2025, the two companies are now deepening their partnership with an ambitious goal: to leverage cutting-edge generative AI technologies to develop innovative drug candidates targeting the central nervous system (CNS).
The initial phase of the collaboration integrated Insilico’s advanced Pharma.AI platform—an AI-powered drug discovery engine capable of generating novel small molecules—with Tenacia’s deep scientific expertise and proprietary data in neurological disease biology. This synergy has allowed both companies to focus on designing small-molecule inhibitors characterized by excellent blood-brain barrier (BBB) permeability, which is critical for CNS drug development. The collaboration is advancing smoothly toward delivering potent candidates that address substantial unmet clinical needs in neurology.
Now, under the expanded agreement, these biopharmaceutical innovators intend to jointly apply generative AI to design an additional novel drug candidate exhibiting precisely defined physicochemical and pharmacokinetic properties tailored to tackle highly challenging neurological diseases. They aim to progress this candidate through early preclinical development stages, referred to as the preclinical candidate (PCC) phase, where efficacy, safety, and developability profiles are comprehensively evaluated. This approach represents a strategic endeavor to diversify the therapeutic pipeline by exploring molecules with distinct and complementary biological profiles.
By targeting molecules with differentiated mechanisms or binding profiles, the partnership seeks to mitigate the historically high attrition rates found in CNS drug development. This dual-pronged AI-driven strategy not only reduces late-stage clinical failure risk but also expands the therapeutic arsenal for treating complex nervous system disorders—offering hope for more precise, effective, and safer interventions in conditions notoriously recalcitrant to existing therapies.
The financial scope of this expanded collaboration is notable, carrying an additional potential deal value of up to US$94.75 million. This structure includes near-term payments and milestone-based incentives, positioning Insilico to benefit from significant value realization as key research and development milestones are achieved. Such economic frameworks reflect the increasing industry confidence in AI’s transformative potential to expedite drug discovery timelines while improving candidate success probabilities.
Alex Zhavoronkov, PhD, the founder, CEO, and Chief Business Officer of Insilico Medicine, underscored the transformative impact of generative AI in modern pharmaceutical research. He emphasized that launching a second drug development program for the same target with distinct attributes within a brief time frame exemplifies the platform’s versatility and power. Zhavoronkov highlighted the symbiotic integration of Tenacia’s CNS domain knowledge with Insilico’s Pharma.AI capabilities, which continues to generate solutions possessing strong translational potential — an essential prerequisite for clinical success and patient benefit.
From Tenacia’s perspective, this collaboration epitomizes their unwavering commitment to innovation in neurological drug discovery. Leveraging advanced computational methods alongside traditional expertise has proven crucial in surmounting existing research and development barriers. The partnership with Insilico is viewed not only as a scientific opportunity but as a strategic imperative to deliver differentiated therapeutic options to patients suffering from otherwise neglected nerve system diseases.
Insilico’s expanding foothold in CNS drug discovery extends beyond this agreement. In early 2026, the company entered into a co-development deal with Hygtia Therapeutics—a joint venture formed by Fosun Pharma—to advance ISM8969, a drug candidate targeting the NLRP3 inflammasome pathway, which plays a pivotal role in neuroinflammatory and neurodegenerative disorders, including Parkinson’s disease. This program, eligible for significant milestone and upfront payments totaling over HK$500 million, achieved a crucial milestone with FDA clearance to commence clinical trials in January 2026. Such achievements underscore Insilico’s commitment and capability to translate AI-designed molecules from concept through regulatory approval.
Founded in 2022 by Bain Capital, Tenacia Biotechnology has rapidly evolved into a commercial-stage biopharmaceutical enterprise driven by decades of drug development expertise from a seasoned team. Their platform integrates a comprehensive understanding of disease biology with innovative neuroscience research methodologies, enabling accelerated advancement of novel therapies for complex CNS conditions. The strong financial backing and strategic vision of Bain Capital underpin Tenacia’s capacity to make sustained investments in cutting-edge neuroscience R&D.
Insilico Medicine’s proprietary Pharma.AI platform stands out as an end-to-end AI-driven discovery engine that combines generative models, reinforcement learning, and deep learning algorithms with vast datasets encompassing biological pathways, disease mechanisms, and chemical space. This integration fosters automated design, optimization, and prioritization of drug candidates, drastically reducing the timelines traditionally required for small molecule development. Importantly, the ability to incorporate complex BBB permeability modeling is paramount to success in CNS drug design.
Together, Insilico and Tenacia represent a new paradigm in biotechnology: the seamless integration of artificial intelligence-driven computational methods with domain-specific biological expertise to overcome longstanding challenges in CNS therapeutics. The expanded program marks a crucial step forward, potentially setting new standards for efficiency, precision, and innovation in drug discovery aimed at neurological diseases that affect millions worldwide.
As this collaboration advances, the global scientific and medical communities watch closely, optimistic that such AI-empowered partnerships can accelerate the delivery of transformative therapies to patients suffering from debilitating neurological conditions. The novel candidates emerging from this alliance could redefine treatment landscapes and greatly improve clinical outcomes in diseases that have long defied effective intervention.
Subject of Research:
Artificial Intelligence-Driven Drug Discovery for Central Nervous System Disorders
Article Title:
Insilico Medicine and Tenacia Biotechnology Expand AI-Driven Collaboration to Develop Innovative CNS Therapeutics with $94.75 Million Deal Value
News Publication Date:
March 2026
Web References:
https://insilico.com/
Image Credits:
Insilico Medicine
Keywords:
Generative AI, Central Nervous System, Small Molecules, Drug Design, Blood-Brain Barrier, Preclinical Candidate, Neurological Diseases, CNS Therapeutics, Artificial Intelligence, Pharma.AI, Drug Discovery, Neurodegenerative Disorders
